Scholar Rock wins FDA approval for ISEMBYLD, first muscle-targeted SMA treatment

Scholar Rock Holding Corporation announced on September 11 that the U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) to treat spinal muscular atrophy in adults and children ages 2 and older who are currently receiving a survival motor neuron 2, or SMN2, targeted treatment. The company describes ISEMBYLD as the first and only approved muscle-targeted treatment to demonstrate motor function improvement in people with SMA receiving that background therapy. The approval is a regulatory and commercial milestone for the Nasdaq-listed company, whose ticker is SRRK (Form 8-K AccNo 0001104659-26-107273).

FDA approval opens the U.S. launch

The treatment's place alongside existing therapy is central to the announcement. Its approved indication requires patients to be receiving an SMN2-targeted treatment; the approval does not position ISEMBYLD as a replacement for that treatment. Scholar Rock says its U.S. commercial launch is underway and product will be available to ship in the coming days. That statement establishes the company's launch plans, while leaving actual shipment volumes and the pace of patient uptake unreported.

The announcement and filing dates are distinct. The approval release is dated September 11, 2026, which is also the earliest event date reported in the Form 8-K. The filing surfaced on September 14 at approximately 8 a.m. Eastern time. Scholar Rock also scheduled an investor call for September 14 at 8 a.m. Eastern and furnished an accompanying presentation. Those later disclosures should not be mistaken for a September 14 approval announcement.

What the SAPPHIRE results show

The approval announcement cites the randomized, double-blind, placebo-controlled Phase 3 SAPPHIRE study, which met its primary endpoint. In the main efficacy population of 103 children ages 2 through 12, ISEMBYLD at 10 mg/kg plus SMN2-targeted treatment produced a 2.2-point improvement versus SMN2-targeted treatment alone on the Hammersmith Functional Motor Scale-Expanded, or HFMSE, at one year. The reported nominal p-value was 0.0121. Scholar Rock characterized that difference as clinically meaningful. The 2.2-point figure is the reported comparison between treatment groups, rather than a claim that every treated patient improved by that amount.

A responder analysis provides another view of the motor function findings. An HFMSE increase of at least 3 points occurred in 34.2% of patients receiving ISEMBYLD, compared with 13.5% in the placebo group. The reported odds ratio was 3.8, with a nominal p-value of 0.0125. The two percentages describe the share reaching the specified threshold; they do not mean that all patients receiving ISEMBYLD experienced that degree of improvement. Both the primary result and the responder analysis should retain the release's nominal p-value qualification.

The age range in that main efficacy analysis is narrower than the approved indication. The reported primary endpoint population was ages 2 through 12, while the approval covers adults as well as children ages 2 and older who meet the background-treatment requirement. Keeping those populations separate avoids presenting the pediatric subgroup result as a separately reported estimate for every age covered by the label. The recommended dose cited in the release is 10 mg/kg.

Safety and treatment access

Scholar Rock described the safety profile as well-characterized, citing a database of more than 500 individuals across apitegromab studies globally, including some treated for more than seven years. It also reported that 98% of SAPPHIRE participants elected to continue into the ONYX long-term extension. That continuation rate describes participation in further follow-up; it is not an additional measure of efficacy or proof that treatment carries no risk.

The release lists upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis and hypersensitivity among common adverse reactions. It also reports fractures in 9% of patients receiving ISEMBYLD 10 mg/kg, versus 2% receiving placebo. Those reported safety findings belong alongside the motor function results when describing the approval.

Scholar Rock says its Scholar Rock Supports patient support program is available. Depending on eligibility, infusion settings may include a hospital, the home or an infusion center. The release directs readers to ISEMBYLD.com and ScholarRockSupports.com and lists 833-777-5444 for support. The availability of a support program and potential infusion settings does not establish how broadly insurers will cover treatment or what an individual patient's access arrangements will be.

A voucher award, with commercial questions still open

The FDA approval also brought Scholar Rock a Rare Pediatric Disease Priority Review Voucher. The voucher may be used to obtain priority review for a future marketing application. The verified announcement does not establish a sale, a transaction value or any other disposition of the voucher, so the award should be understood as part of the regulatory milestone rather than as a completed monetization event.

The immediate commercial development is the U.S. launch. The supplied facts do not establish list or net pricing, payer coverage breadth, day-one shipment volumes or a sales forecast. They also do not support a market-share comparison with other SMA treatments. Those gaps limit what can be concluded about the financial scale or speed of the launch, even though FDA approval has moved the product into a new commercial phase.

The geographic boundary is equally clear: the furnished presentation states that apitegromab has not been approved for any use by a regulatory agency other than the FDA. This is a U.S. approval story, with no established European approval or timetable for other jurisdictions. In the 8-K, Item 8.01 restates the approval, while the release and investor slides are furnished under Item 7.01. The presentation's forward-looking statements should not be read as completed commercial results.

Filing reference

Scholar Rock Holding Corporation disclosed the FDA approval of ISEMBYLD (apitegromab-mstn) in Form 8-K AccNo 0001104659-26-107273 (Items 7.01, 8.01 and 9.01; earliest event September 11, 2026; filed September 14, 2026), with Exhibit 99.1 press release and Exhibit 99.2 investor-call slides furnished under Item 7.01.